# Plaque Psoriasis Efficacy and Safety With Secukinumab

> **NCT02409667** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 16487 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **BIOLOGICAL:** Secukinumab

## Key facts

- **NCT ID:** NCT02409667
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-07
- **Primary completion:** 2017-03-14
- **Final completion:** 2017-05-08
- **Target enrollment:** 16487 (ACTUAL)
- **Last updated:** 2019-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02409667

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02409667, "Plaque Psoriasis Efficacy and Safety With Secukinumab". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02409667. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*